MedPath

NBE-Therapeutics AG

NBE-Therapeutics AG logo
🇨🇭Switzerland
Ownership
Subsidiary
Established
2012-01-01
Employees
11
Market Cap
-
Website
http://www.nbe-therapeutics.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

NBE-002 in Patients With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Advanced Solid Tumor
Triple Negative Breast Cancer
Advanced Cancer
Interventions
First Posted Date
2020-06-22
Last Posted Date
2023-09-07
Lead Sponsor
NBE-Therapeutics AG
Target Recruit Count
12
Registration Number
NCT04441099
Locations
🇺🇸

Sarah Cannon Research Institute - TN Oncology, Nashville, Tennessee, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.